| Stage | PSA | % of rev | PCG | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.4B | 100.00% | $6.2B | 100.00% | PCG ×4.53 |
| Gross profit | $989M | 72.41% | $2.6B | 42.53% | PSA +29.9pp |
| Operating income | $317M | 23.20% | $1.2B | 20.18% | PSA +3.0pp |
| Pre-tax income | $363M | 26.59% | $681M | 11.01% | PSA +15.6pp |
| Net income | $378M | 27.69% | $776M | 12.54% | PSA +15.2pp |
| Stage | PSA | PCG | Gap · A − B |
|---|---|---|---|
| Revenue | $1.4B100.00% | $6.2B100.00% | PCG ×4.53 |
| Gross profit | 72.41%$989M | 42.53%$2.6B | PSA +29.9pp |
| Operating income | 23.20%$317M | 20.18%$1.2B | PSA +3.0pp |
| Pre-tax income | 26.59%$363M | 11.01%$681M | PSA +15.6pp |
| Net income |
| 27.69%$378M |
| 12.54%$776M |
| PSA +15.2pp |